Retapamulin: Difference between revisions
Gerald Chi (talk | contribs) m (→Overview) |
Gerald Chi (talk | contribs) m (→Category) |
||
| Line 12: | Line 12: | ||
==Category== | ==Category== | ||
Antibacterial | |||
==US Brand Names== | ==US Brand Names== | ||
Revision as of 21:37, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.
Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency for the same indication.
Clinical trials have demonstrated its efficacy against certain Gram-positive bacteria including MRSA.[1]
Category
Antibacterial
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ Jones R, Fritsche T, Sader H, Ross J (2006). "Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci". Antimicrob Agents Chemother. 50 (7): 2583–6. doi:10.1128/AAC.01432-05. PMC 1489758. PMID 16801451.